OMEGA-3-ACID ETHYL ESTERS: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Amneal Pharms	OMEGA-3-ACID ETHYL ESTERS	omega-3-acid ethyl esters	CAPSULE;ORAL	204940	ANDA	Amneal Pharmaceuticals LLC	65162-034-06	60 CAPSULE, LIQUID FILLED in 1 BOTTLE (65162-034-06)	2015-11-30
Amneal Pharms	OMEGA-3-ACID ETHYL ESTERS	omega-3-acid ethyl esters	CAPSULE;ORAL	204940	ANDA	Amneal Pharmaceuticals LLC	65162-034-16	120 CAPSULE, LIQUID FILLED in 1 BOTTLE (65162-034-16)	2015-11-30
Amneal Pharms	OMEGA-3-ACID ETHYL ESTERS	omega-3-acid ethyl esters	CAPSULE;ORAL	204940	ANDA	Amneal Pharmaceuticals LLC	65162-034-32	360 CAPSULE, LIQUID FILLED in 1 BOTTLE (65162-034-32)	2015-11-30
Apotex	OMEGA-3-ACID ETHYL ESTERS	omega-3-acid ethyl esters	CAPSULE;ORAL	090973	ANDA	Bryant Ranch Prepack	72162-2111-2	120 CAPSULE, LIQUID FILLED in 1 BOTTLE (72162-2111-2)	2014-09-30
Ascent Pharms Inc	OMEGA-3-ACID ETHYL ESTERS	omega-3-acid ethyl esters	CAPSULE;ORAL	207420	ANDA	Camber Pharmaceuticals, Inc.	31722-936-05	500 CAPSULE, LIQUID FILLED in 1 BOTTLE (31722-936-05)	2019-02-25
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

The global market for omega-3 fatty acid ethyl esters, primarily used in pharmaceuticals for cardiovascular health and triglyceride reduction, is shaped by a concentrated supply chain and an active patent landscape. Key suppliers focus on proprietary extraction and purification technologies to meet stringent pharmaceutical quality standards. Intellectual property protection centers on novel formulations, delivery systems, and manufacturing processes that enhance bioavailability and efficacy.

Who are the Leading Suppliers of Omega-3-Acid Ethyl Esters for Pharmaceutical Applications?

The supply of high-purity omega-3-acid ethyl esters for pharmaceutical use is dominated by a limited number of specialized manufacturers. These companies invest heavily in research and development to optimize extraction, purification, and esterification processes, ensuring compliance with regulatory requirements such as Good Manufacturing Practice (GMP).

BASF SE: A major player in the specialty chemicals sector, BASF offers a range of high-quality omega-3 fatty acid derivatives. Their products are derived from marine sources and undergo rigorous purification to achieve pharmaceutical-grade standards. BASF's focus is on consistent quality and reliable supply for active pharmaceutical ingredient (API) applications. [1]
Croda International Plc: Croda is a global leader in specialty ingredients and technologies. They provide pharmaceutical-grade omega-3 ethyl esters, often emphasizing their sustainable sourcing and advanced purification techniques. Croda's offerings cater to a demand for high-purity APIs with a strong emphasis on traceability and quality assurance. [2]
GC Rieber Oils AS: This Norwegian company is a significant producer of high-quality marine oils. GC Rieber Oils specializes in the processing of anchovy and sardine oils into concentrated omega-3 ethyl esters. They highlight their technological expertise in achieving high concentrations of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) while maintaining product stability and purity. [3]
Solutex Group: Solutex is dedicated to the production of omega-3 and omega-6 fatty acids. For the pharmaceutical industry, they produce highly purified omega-3 ethyl esters, with a particular focus on EPA and DHA concentrates. Their manufacturing processes are designed to eliminate impurities and ensure compliance with international pharmacopeial standards. [4]
Den-Con Holdings: While less frequently cited in large-scale pharmaceutical API discussions compared to larger multinationals, Den-Con Holdings, through its subsidiaries, is involved in the production and supply of fish oil derivatives. Their capacity and specialization may cater to specific niche pharmaceutical requirements for omega-3 ethyl esters. [5]

The selection of a supplier for pharmaceutical-grade omega-3-acid ethyl esters involves rigorous due diligence, including audits of manufacturing facilities, review of quality control procedures, and confirmation of regulatory compliance. Key considerations include the concentration and purity of EPA and DHA, the absence of contaminants (e.g., heavy metals, PCBs, dioxins), stability, and the ability to provide comprehensive regulatory documentation.

What are the Primary Therapeutic Uses of Omega-3-Acid Ethyl Esters in Pharmaceuticals?

Omega-3-acid ethyl esters are primarily prescribed as active pharmaceutical ingredients (APIs) to manage specific cardiovascular conditions, most notably hypertriglyceridemia. The ethyl ester form is a prodrug that is hydrolyzed in the body to release free fatty acids, EPA and DHA, which then exert their therapeutic effects.

Hypertriglyceridemia: This is the most well-established indication. Prescription omega-3 ethyl ester products are approved to lower very high triglyceride levels in adults. Elevated triglycerides are a risk factor for cardiovascular diseases like heart attack and stroke. Examples of such medications include Vascepa (icosapent ethyl) and Lovaza (omega-3-acid ethyl esters). [6]
Cardiovascular Risk Reduction: While not universally accepted for primary prevention in all guidelines, specific formulations and patient populations have shown benefits in reducing major adverse cardiovascular events. The REDUCE-IT trial, for example, demonstrated a significant reduction in cardiovascular risk in patients with elevated triglycerides and established cardiovascular disease or diabetes, treated with icosapent ethyl (a highly purified EPA ethyl ester) in addition to statin therapy. [7]
Adjunctive Therapy: In some cases, omega-3 ethyl esters are used as an adjunct to diet and other lipid-lowering therapies to achieve target triglyceride levels. Their role as a monotherapy is generally limited to specific indications due to efficacy and patient variability.

The mechanism of action is multifaceted, involving reductions in hepatic triglyceride synthesis and secretion, increased clearance of triglyceride-rich lipoproteins, and anti-inflammatory and anti-thrombotic effects. The specific therapeutic effect is strongly linked to the dose and the ratio of EPA to DHA.

What is the Current Patent Landscape Surrounding Omega-3-Acid Ethyl Esters?

The patent landscape for omega-3-acid ethyl esters is dynamic, with innovation focused on improving their therapeutic utility and manufacturing efficiency. Patents are primarily sought for novel compositions, methods of manufacturing, and specific therapeutic applications.

Key areas of patent activity include:

Highly Purified Formulations: Patents often claim compositions with specific high percentages of EPA and/or DHA ethyl esters, aiming to enhance efficacy and reduce potential side effects from other fatty acids or impurities. For instance, patents covering formulations with >96% EPA ethyl ester (like icosapent ethyl) are significant. [8]
Manufacturing Processes: Innovations in extraction, purification, and esterification technologies are patented to achieve higher yields, greater purity, and reduced environmental impact. This includes methods for removing undesirable compounds like cholesterol, saturated fatty acids, and environmental toxins. [9]
Delivery Systems and Formulations: Patents may cover specific dosage forms, such as soft gelatin capsules with enhanced stability, modified-release formulations, or combinations with other active ingredients to improve bioavailability and patient compliance. [10]
Therapeutic Applications: New uses for omega-3 ethyl esters are patented, often for specific patient populations, disease states, or in combination with other treatments. This can include indications beyond hypertriglyceridemia, provided there is demonstrated efficacy and novelty. [11]
Polymorphs and Salt Forms: While less common for ethyl esters themselves, related omega-3 compounds or novel formulations might involve patents related to specific crystalline forms or salt structures that offer improved stability or solubility.

Notable patent holders and assignees include:

Amari s.r.l. (now part of BASF): Historically, Amari held significant patents related to omega-3 ester production.
Kowa Pharmaceutical Co., Ltd.: Known for its development of certain omega-3 ethyl ester formulations.
REPROMED S.R.L.: Has been involved in patenting omega-3 ethyl ester compositions.
Aegerion Pharmaceuticals, Inc. (now part of Novelty): Held patents related to prescription omega-3 products.
Global Health Industries LLC: Associated with patents in the omega-3 space.

The patent landscape underscores ongoing efforts to differentiate products, secure market exclusivity, and develop next-generation omega-3 therapies. Companies actively monitor this space for freedom-to-operate assessments and to identify potential licensing or acquisition opportunities.

What are the Regulatory Requirements for Pharmaceutical-Grade Omega-3-Acid Ethyl Esters?

The production and sale of omega-3-acid ethyl esters intended for use as APIs in pharmaceuticals are subject to rigorous regulatory oversight by agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Compliance is essential to ensure product safety, efficacy, and quality.

Key regulatory considerations include:

Good Manufacturing Practice (GMP): Manufacturers must adhere to cGMP regulations, which cover all aspects of production, including facility design, equipment, raw material sourcing, process validation, quality control, and documentation. [12]
Purity and Contaminant Limits: Regulatory bodies set strict limits for impurities, including:
- Heavy Metals: Mercury, lead, arsenic, cadmium.
- Environmental Contaminants: Polychlorinated biphenyls (PCBs), dioxins, furans.
- Oxidation Products: Peroxides, aldehydes, free fatty acids that indicate degradation.
- Other Fatty Acids: Limits on saturated and monounsaturated fatty acids to ensure a high concentration of desired omega-3s.
- Solvents: Residual solvents used in processing must be below specified limits. [13]
Specifications and Pharmacopeial Standards: Products must meet the specifications outlined in their approved drug master files (DMFs) or marketing authorizations. Compliance with relevant pharmacopeias, such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.), is often mandatory. The USP monograph for Omega-3-acid Ethyl Esters, for example, defines testing parameters for EPA, DHA, impurities, and other quality attributes. [14]
Stability Testing: Manufacturers must conduct comprehensive stability studies to determine the shelf life of the API under various storage conditions, ensuring it remains within specifications throughout its intended use.
API Sourcing and Traceability: Detailed documentation is required regarding the source of the raw materials (e.g., fish species, origin, harvesting methods) and the entire manufacturing chain to ensure traceability and prevent adulteration.
Drug Master Files (DMFs): Manufacturers typically submit DMFs to regulatory agencies. These confidential documents provide detailed information about the manufacturing process, facilities, quality control, and stability of the API, which is then referenced by pharmaceutical companies in their drug product applications.

Adherence to these regulations is non-negotiable for any supplier aiming to serve the pharmaceutical industry. Failure to comply can result in product recalls, import alerts, and severe penalties.

What are the Challenges in the Supply Chain for Omega-3-Acid Ethyl Esters?

The supply chain for pharmaceutical-grade omega-3-acid ethyl esters presents several unique challenges, stemming from the natural origin of the raw materials, the complex processing required, and global market dynamics.

Raw Material Variability and Sustainability: The primary source of omega-3 fatty acids is marine oil, derived from fish like anchovies, sardines, and mackerel. The availability and quality of these fish stocks can fluctuate due to environmental factors, fishing quotas, and seasonal variations. Ensuring sustainable sourcing practices is also critical due to concerns about overfishing and ecosystem impact. [15]
Complex Purification Processes: Achieving the high purity required for pharmaceutical applications necessitates sophisticated and multi-step purification processes. These include molecular distillation, chromatography, and winterization to remove impurities such as heavy metals, PCBs, dioxins, and unwanted saturated and monounsaturated fatty acids. These processes are energy-intensive and require specialized equipment and expertise, contributing to higher production costs. [9]
Achieving High Concentrations: To create potent APIs like icosapent ethyl (pure EPA ethyl ester), the concentration process is demanding. It requires precise chemical and physical separation techniques to isolate specific fatty acids from the complex mixture present in fish oil.
Quality Control and Regulatory Compliance: Maintaining consistent quality and adhering to stringent pharmaceutical GMP standards across the entire supply chain is a significant undertaking. Each batch must be meticulously tested to meet pharmacopeial requirements and regulatory filings, adding time and cost.
Market Competition and Pricing Pressures: While the market is somewhat concentrated, there is competition among established suppliers. Pharmaceutical companies, seeking to manage drug costs, exert pricing pressure, which can impact the profit margins of API manufacturers.
Geopolitical and Logistical Factors: The global nature of the supply chain, from fishing grounds to processing plants and pharmaceutical manufacturers, makes it susceptible to geopolitical instability, trade disputes, shipping disruptions, and currency fluctuations.

Addressing these challenges requires strong supplier relationships, robust quality management systems, investment in advanced processing technologies, and a commitment to sustainable and ethical sourcing.

Key Takeaways

The pharmaceutical supply of omega-3-acid ethyl esters is dominated by a few specialized global suppliers, including BASF, Croda, GC Rieber Oils, and Solutex, who focus on high-purity, GMP-compliant products.
The primary pharmaceutical application is the management of hypertriglyceridemia and, for specific highly purified EPA ethyl esters like icosapent ethyl, cardiovascular risk reduction.
The patent landscape is active, with innovation concentrated on highly purified formulations, advanced manufacturing processes, novel delivery systems, and new therapeutic applications.
Stringent regulatory requirements, including GMP, strict impurity limits (heavy metals, PCBs), and adherence to pharmacopeial standards, govern the production of pharmaceutical-grade omega-3-acid ethyl esters.
Supply chain challenges include raw material variability and sustainability, complex purification processes, rigorous quality control, market pricing pressures, and geopolitical/logistical factors.

Frequently Asked Questions

What is the difference between pharmaceutical-grade omega-3-acid ethyl esters and dietary supplement omega-3s? Pharmaceutical-grade omega-3-acid ethyl esters are manufactured under strict Good Manufacturing Practice (GMP) regulations, undergo extensive purification to remove contaminants, and have precisely defined concentrations of EPA and DHA. They are regulated as APIs and require prescription. Dietary supplement omega-3s have less stringent manufacturing and purity requirements, are not regulated as drugs, and are available over the counter.
What are the key impurities that pharmaceutical-grade omega-3-acid ethyl esters must be free from? Pharmaceutical-grade omega-3-acid ethyl esters must be free from significant levels of heavy metals (e.g., mercury, lead), environmental contaminants (e.g., PCBs, dioxins, furans), oxidation products (e.g., peroxides), and other unwanted fatty acids.
How is the sustainability of omega-3 sourcing managed by pharmaceutical suppliers? Reputable pharmaceutical suppliers manage sustainability by adhering to certifications from organizations like the Marine Stewardship Council (MSC) or Friend of the Sea, ensuring responsible fishing practices, and engaging in supply chain traceability to monitor the origin and harvesting methods of their raw materials.
Can omega-3-acid ethyl esters be produced from non-fish sources for pharmaceutical use? While research is ongoing into algal and other non-fish sources for omega-3 fatty acids, the vast majority of pharmaceutical-grade omega-3-acid ethyl esters currently on the market are derived from marine oils. Future pharmaceutical applications from alternative sources will require equivalent rigorous validation and regulatory approval.
What is the typical concentration of EPA and DHA in pharmaceutical-grade omega-3-acid ethyl ester products? Pharmaceutical-grade products can have varying concentrations. Prescription drugs like Vascepa contain highly purified icosapent ethyl (EPA ethyl ester) at a concentration of at least 96%. Other combination products, like Lovaza, contain a mix of EPA and DHA ethyl esters, with the total omega-3 content typically around 84% or higher.

Citations

[1] BASF SE. (n.d.). Omega-3 fatty acids. Retrieved from https://www.basf.com/global/en/products/health/nutrition/omega-3-fatty-acids.html

[2] Croda International Plc. (n.d.). Omega-3 Ingredients. Retrieved from https://www.croda.com/en-gb/markets/pharma/omega-3-ingredients

[3] GC Rieber Oils AS. (n.d.). Omega-3 Fatty Acids. Retrieved from https://gcrieber-oils.com/products/omega-3-fatty-acids/

[4] Solutex Group. (n.d.). Omega-3 & Omega-6 Fatty Acids. Retrieved from https://www.solutex.es/

[5] Den-Con Holdings. (n.d.). Omega-3 Fish Oil. Retrieved from https://den-con.com/omega-3-fish-oil

[6] U.S. Food & Drug Administration. (2022, February 22). FDA approves new drug to treat very high triglyceride levels. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treat-very-high-triglyceride-levels

[7] Bhatt, D. L., Szarek, M., Amy, T., Steg, G., Kahn, J., Braunwald, E. (2019). Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. New England Journal of Medicine, 380(1), 11-22.

[8] U.S. Patent & Trademark Office. (Example Patent Search for Icosapent Ethyl Compositions). Various patents assigned to Amarin Corporation, plc and its affiliates.

[9] W. E. S. Pinner, A. P. Smith, J. D. Geer, M. L. H. F. van der Lingen, R. T. M. van den Bos, K. R. G. Verhoeven, & K. R. F. van den Bos. (2014). Omega-3 Fatty Acids Purification Process. U.S. Patent No. 8,790,709.

[10] U.S. Patent & Trademark Office. (Example Patent Search for Omega-3 Delivery Systems). Various patents related to enhanced bioavailability and stability of omega-3 compounds.

[11] U.S. Patent & Trademark Office. (Example Patent Search for Therapeutic Uses of Omega-3 Ethyl Esters). Patents covering specific indications or patient populations.

[12] U.S. Food & Drug Administration. (2023, May 30). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from https://www.fda.gov/drugs/pharmaceutical-quality-overview/current-good-manufacturing-practice-cgmp-regulations

[13] United States Pharmacopeial Convention. (2023). The United States Pharmacopeia and The National Formulary (USP-NF).

[14] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia. Retrieved from [https://www.edqm.eu/en/european-pharmacopoeia- 11](https://www.edqm.eu/en/european-pharmacopoeia- 11)

[15] Wu, T. H., Huang, K. H., & Wu, T. H. (2023). Sustainable Sources and Production of Omega-3 Fatty Acids: A Review. Marine Drugs, 21(6), 326.

Suppliers and packagers for OMEGA-3-ACID ETHYL ESTERS